Sugi Predict

Sugi Predict / Compounds / SCHEMBL4336263

SCHEMBL4336263

SCHEMBL4336263

NC(=S)N/N=C/c1cc(F)c(N2CCN(Cc3cccc(F)c3)CC2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ NPY2R P49146 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PHGDH O43175 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ FAAH O00519 1/20 0.40
▸ DRD2 P14416 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336270 1.00 MAOB (0.47) MAOBALDH1A1KMT2AMEN1HSD17B10
SCHEMBL4322300 0.91 ALDH1A1 (0.48) MAOBALDH1A1KMT2APKML3MBTL1
SCHEMBL4322284 0.91 ALDH1A1 (0.48) MAOBALDH1A1KMT2APKML3MBTL1
SCHEMBL4325311 0.91 L3MBTL1 (0.52) MAOBALDH1A1KMT2AL3MBTL1GAA
SCHEMBL4325307 0.91 L3MBTL1 (0.52) MAOBALDH1A1KMT2AL3MBTL1GAA
SCHEMBL4336679 0.90 LMNA (0.45) MAOBALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL4336683 0.90 LMNA (0.45) MAOBALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL4557110 0.89 MAOB (0.43) MAOBALDH1A1KMT2APKML3MBTL1
SCHEMBL4557106 0.89 MAOB (0.43) MAOBALDH1A1KMT2APKML3MBTL1
SCHEMBL4331055 0.87 L3MBTL1 (0.48) MAOBALDH1A1KMT2AL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885ALDH1A1 1459/4885KMT2A 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.